Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Sells $119,629.00 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 2,635 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $45.40, for a total transaction of $119,629.00. Following the sale, the chief financial officer now directly owns 96,470 shares in the company, valued at approximately $4,379,738. This trade represents a 2.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jack Anders also recently made the following trade(s):

• On Friday, October 11th, Jack Anders sold 10,000 shares of Revolution Medicines stock. The shares were sold at an average price of $50.30, for a total value of $503,000.00.

Revolution Medicines Trading Up 1.8 %

Shares of NASDAQ:RVMD opened at $44.06 on Friday. The stock has a market capitalization of $7.41 billion, a PE ratio of -12.27 and a beta of 1.40. Revolution Medicines, Inc. has a 1 year low of $25.91 and a 1 year high of $62.40. The firm has a fifty day moving average price of $51.85 and a 200 day moving average price of $46.04.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.05). During the same period in the prior year, the company posted ($0.99) earnings per share. On average, sell-side analysts forecast that Revolution Medicines, Inc. will post -3.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Revolution Medicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in shares of Revolution Medicines by 55.8% in the third quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock valued at $28,000 after purchasing an additional 222 shares during the last quarter. Quarry LP bought a new stake in Revolution Medicines during the 3rd quarter valued at approximately $82,000. Values First Advisors Inc. acquired a new stake in Revolution Medicines in the 3rd quarter valued at approximately $93,000. Nisa Investment Advisors LLC increased its position in Revolution Medicines by 10.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,378 shares of the company’s stock worth $131,000 after buying an additional 320 shares during the period. Finally, KBC Group NV lifted its holdings in shares of Revolution Medicines by 12.9% during the third quarter. KBC Group NV now owns 3,221 shares of the company’s stock worth $146,000 after buying an additional 368 shares during the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

Wall Street Analyst Weigh In

RVMD has been the subject of a number of research reports. Wedbush restated an “outperform” rating and set a $70.00 price objective on shares of Revolution Medicines in a research report on Monday, December 2nd. Piper Sandler raised their price target on shares of Revolution Medicines from $57.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $68.00 price objective on shares of Revolution Medicines in a research report on Tuesday, December 3rd. JPMorgan Chase & Co. increased their target price on shares of Revolution Medicines from $63.00 to $71.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 3rd. Finally, Guggenheim boosted their price target on shares of Revolution Medicines from $82.00 to $87.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $65.82.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.